Conjunctival structure of glaucomatous eyes treated with anti-glaucoma eye drops: a cross-sectional study using anterior segment optical coherence tomography

Table 3 The univariate and general linear mixed model (GLMM) analyses on the conjunctival stroma/Tenon’s capsule preservation rate

a. The effects of background characteristics
	Univariable analysis		Multiple analysis 1
	β	p-value	β	p-value	VIF
Sex (male vs. female)	−0.010	0.867	−0.027	0.377	1.08
Age (years)	−0.008	0.874	0.015	0.593	1.06
Number of anti-glaucoma eye drops	−0.654	< 0.001	− 0.454	< 0.001	1.74
Duration of administration (months)	−0.660	< 0.001	−0.349	< 0.001	1.72
b. The effects of anti-glaucoma eye drops
	Univariable analysis		Multiple analysis 2		Multiple analysis 3
	β	p-value	β	p-value	β	p-value	VIF
Prostaglandin analogs	−0.586	< 0.001	−0.174	0.001	−0.183	< 0.001	1.72
α2-receptor agonist	−0.388	< 0.001	0.142	0.001	0.103	0.021	1.57
Rho kinase inhibitor	−0.150	0.001	0.007	0.824
The fixed combination of β-blockers/CAIs	−0.439	< 0.001	− 0.047	0.251
The fixed combination of β-blockers/prostaglandin analogs	−0.337	< 0.001	− 0.055	0.117	−0.091	0.009	1.33
β-blockers	−0.240	< 0.001	−0.039	0.295
CAIs	−0.243	< 0.001	0.083	0.019

Multiple analysis 1, multiple GLMM analysis with the thickness of the preservation rate and with background characteristics; Multiple analysis 2, multiple GLMM analysis with the preservation rate and with the eye drops after adjusted for confounding factor (number of anti-glaucoma eye drops and duration of administration).; Multiple analysis 3, the stepwise method for variable selection
CAI carbonic anhydrase inhibitors, VIF variance inflation factor

ISSN: 1471-2415